Morphotek Obtains Exclusive License From Micromet For Antibody To Treat Melanoma And Other Cancers

Tue, 13 Feb 2007 02:00 PM EST

... Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, and Morphotek(R) Inc. [click link for full article] ...